These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25429673)

  • 1. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
    Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
    Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Bahar MA; Setiawan D; Hak E; Wilffert B
    Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
    Lu S; Nand RA; Yang JS; Chen G; Gross AS
    Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
    Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
    Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
    Velazquez MNR; Parween S; Udhane SS; Pandey AV
    Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.
    Daly AK
    Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
    Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
    Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Correlation between Genotypes and Hepatic Protein Expression of
    Pedersen KW; Andersen JD; Hansen J; Børsting C; Banner J; Hasselstrøm JB; Jornil JR
    Drug Metab Dispos; 2024 Aug; 52(9):975-980. PubMed ID: 38906700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
    He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
    Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
    de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
    OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula.
    Carano F; Sarno S; De Fanti S; Serventi P; Bini C; Luiselli D; Pelotti S
    Ann Hum Biol; 2018 Feb; 45(1):66-71. PubMed ID: 28971704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.